Datapoint: United Therapeutics to Take On Pulmonary Hypertension With Tyvaso Approval Expansion

With a new FDA approval under its belt, United Therapeutics could have a blockbuster on its hands with the inhaled version of hypertension drug Tyvaso. The drug was approved last week for the treatment of pulmonary hypertension associated with interstitial lung disease. The original version of Tyvaso was approved to treat pulmonary arterial hypertension (PAH) in 2009. For the treatment of PAH, Tyvaso holds covered or better status for 84% of all insured lives under the pharmacy benefit. 5.7% of covered lives have preferred access to Tyvaso without utilization management restrictions.

SOURCE: MMIT Analytics, as of 5/25/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today